Excalipoint Therapeutics, based in Shanghai, is launching with an oversubscribed $68.7 million seed financing round. The biotechnology company’s focus is developing next-generation T-cell engager (TCE) therapies for cancer and autoimmune diseases. Funding will support advancement of Excalipoint’s proprietary technology platforms—namely, TOPAbody, T-Cell Immune Shield, and TCE Probody. Also, the financing addresses a pipeline of six differentiated programs with first- or best-in-class potentia...